1. Home /
  2. Biotechnology

Biotechnology

I Smell a Great Stock in a Stinky Market

I Smell a Great Stock in a Stinky Market

International Flavors & Fragrances is a top-quality name that now sits near a four-year low, despite being poised to set new earnings-per-share records this year and next.

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

Johnson & Johnson's Fine May Be the Pin Prick That Keeps Bleeding

By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.

Zogenix Drops After Acquiring Modis Therapeutics

Zogenix Drops After Acquiring Modis Therapeutics

Zogenix will pay $250 million for the privately held biopharmaceutical company.

Johnson & Johnson Faces Oklahoma Opioid Ruling on Monday

Johnson & Johnson Faces Oklahoma Opioid Ruling on Monday

An Oklahoma judge is expected to issue what will be a landmark ruling Monday on whether Johnson & Johnson will be held responsible for the state's opioid epidemic that officials say led to more than 6,000 deaths over nearly two decades.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen to Acquire Celgene's Otezla for $13.4 Billion in Cash

Amgen will acquire the global rights to Celgene's oral psoriasis treatment Otezla for $13.4 billion in cash, paving the way for Bristol Myers-Squibb to compete its acquisition of Celgene.

A Pair of Rare Disease Biotech Concerns Worth a Good Look

A Pair of Rare Disease Biotech Concerns Worth a Good Look

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.